Diffusion Pharmaceuticals is a clinical-stage biotech company developing new, small-molecule drugs that help regulate the movement of oxygen into tissue by a novel mechanism of action. The Company’s lead drug, trans sodium crocetinate (TSC), uses this novel mechanism to re-oxygenate the microenvironment of solid cancerous tumors, thereby significantly enhancing tumor cells’ response to conventional treatment without additional side effects.
Since its founding in 2001, the Company has assembled an expert team to engage the best resources available for the development, formulation, clinical testing, manufacture, approval, and commercialization of this promising new drug. See the Diffusion Pharmaceuticals LLC Executive Summary.